Vers la page d'accueil
820К+ patients ont reçu de l'aide depuis 2014
50 pays
1,500 cliniques
6K+ avis
3K+ médecins qualifiés

Quel est le Coût du Diagnostic et du Traitement de la maladie d'Alzheimer en Chine ?

Le prix est donné sur demande
ChineTurquieEspagne
Traitement de la maladie d'Alzheimer à l'aide de cellules souchesde $22,000de $15,000de $20,000
Données vérifiées par Bookimed en May 2026, sur la base des demandes des patients et des devis officiels de 137 cliniques dans le monde. Les coûts médians sont calculés à partir de factures réelles (2025–2026) et mis à jour chaque mois. Les prix réels peuvent varier.

Vos avantages et garanties avec Bookimed

Prix directs

Bookimed ne rajoute pas de frais pour les traitements de La maladie d'Alzheimer. Les tarifs proviennent des listes de prix officielles des cliniques. Vous payez directement à la clinique pour votre traitement à votre arrivée dans le pays.

Cliniques et médecins vérifiés uniquement

Bookimed s'engage pour votre sécurité. Nous ne travaillons qu'avec des établissements médicaux qui respectent des normes internationales élevées dans le traitement de La maladie d'Alzheimer et qui possèdent les licences nécessaires pour accueillir des patients internationaux dans le monde entier.

Assistance gratuite 24/7

Bookimed offre une assistance experte gratuite. Un coordinateur médical personnel vous accompagne avant, pendant et après votre traitement, en résolvant tous les problèmes. Vous n'êtes jamais seul dans votre parcours de traitement de La maladie d'Alzheimer.

Pourquoi nous ?

Votre coordinateur médical personnel

  • Vous soutient à chaque étape
  • Aide à choisir la bonne clinique et le bon médecin
  • Assure un accès rapide et pratique à l'information

Découvrez les Meilleures Cliniques pour le Traitement de la maladie d'Alzheimer en Chine : 1 Options Vérifiées et Prix

Le classement des cliniques Bookimed est basé sur des algorithmes de science des données, offrant une comparaison fiable, transparente et objective. Il prend en compte la demande des patients, les notes d'évaluation (positives et négatives), la fréquence des mises à jour des options de traitement et des prix, la vitesse de réponse et les certifications des cliniques.

Obtenez une évaluation médicale La maladie d'Alzheimer en en Chine : consultez des médecins expérimentés maintenant

Voir tous les médecins
Vérifié

Zheng Wei Hong

45 années d'expérience

Professor ZHENG Wei Hong is Director of the Department of Neurology and the discipline leader. He previously served as Director of Neurology at Xiamen University Affiliated Zhongshan Hospital. He is a Professor at Xiamen University and a master's supervisor.

His clinical focus includes etiological investigation, prevention, and treatment of cerebral infarction and cerebral hemorrhage. He also diagnoses and treats complex neurological diseases, including epilepsy, neuroimmunological and neuromuscular disorders (myasthenia gravis, multiple sclerosis), and Parkinson's disease.

Appointments: He serves as a committee member of the Neuroimmunology Group (Chinese Medical Association Neurology Branch), the Immunology Branch (Chinese Stroke Association), Neurorestoration (Chinese Medical Doctor Association), and Cognitive Impairment (Chinese Geriatrics Society). He is on the Standing Committee of the Expert Committee of Stroke Screening and Prevention Engineering Base Hospitals (Ministry of Health). He is a member of the Neurology Expert Group, Fujian Provincial Medical Quality Control Center for Stroke and Epilepsy. He is Standing Director of the Fujian Anti‑Epilepsy Association. He is Deputy Group Leader of the Epilepsy and Electroencephalography Group (Fujian Medical Association Neurology Branch). He is Deputy Chairperson of the 1st Committee, Neurology Physicians Branch (Fujian Medical Doctor Association). He is a Standing Committee Member (5th–7th) of the Neurology Branch (Fujian Medical Association). He is Deputy Chairperson of the Neurology Professional Committee (Xiamen Medical Association).

Vérifié

Shao Ming

32 années d'expérience

Neurologue de premier plan et docteur en sciences médicales, ayant suivi une formation postdoctorale à l'université de Harvard et dans d'autres institutions prestigieuses.

  • 31 ans d'expérience en neurologie
  • Auteur de plus de 50 articles scientifiques, dont 30 dans des revues internationales
  • A introduit le propofol pour le test de Wada en Chine
  • Président de multiples comités neurologiques en Chine
  • Spécialisé dans l'épilepsie, les troubles du mouvement et le monitorage neurophysiologique

Partager ce contenu

Histoires vidéo des patients de Bookimed

Dayana
J'ai combiné mes vacances à Antalya avec un bilan de santé.
Procédure: Bilan féminin
Igor
C'était génial ! Transferts, hébergement, traitement – tout était inclus.
Procédure: Implant dentaire
Clinique: WestDent Clinic
Marina
Bookimed s’est occupé de tout. Je n’avais aucun souci à me faire.
Procédure: Bilan féminin
Mis à jour: 10/23/2024
Rédigé par
Anna Leonova
Anna Leonova
Responsable de l'équipe marketing de contenu
Auteur médical certifié avec 10+ ans d'expérience, créateur des contenus fiables de Bookimed, soutenus par un Master en philologie et des interviews avec des experts médicaux internationaux.
Fahad Mawlood
Éditeur Médical et Scientifique des Données
Praticien généraliste. Lauréat de 4 prix scientifiques. Diplômé en Asie occidentale. Ancien Chef d'une équipe médicale aidant les patients arabes. Aujourd'hui responsable du traitement des données et de l'exactitude du contenu médical.
Fahad Mawlood Linkedin
Cette page peut contenir des informations relatives à diverses conditions médicales, traitements et services de santé disponibles dans différents pays. Veuillez noter que le contenu est fourni à des raisons d'information seulement et ne devrait pas être interprété comme conseil médical. Veuillez consulter votre médecin ou un professionnel de la santé qualifié avant d'entreprendre ou de changer de traitement médical.

FAQ sur le Traitement de la maladie d'Alzheimer en Chine

Ces FAQ sont basées sur les questions de patients réels cherchant des soins médicaux avec Bookimed. Les réponses sont fournies par des experts médicaux et des représentants de cliniques réputées.

Is Alzheimer’s disease treatment in China safe for international patients?

Alzheimer’s disease treatment in China is safe when patients choose accredited tertiary facilities like Dr. Eber Brain Hospital. These centers employ specialists with training from Harvard and UT. Standard protocols include globally approved monoclonal antibodies. Patients must prioritize JCI or ISO-certified hospitals to ensure Western-level safety standards.

  • Specialized expertise: Neurologists like Dr. Shao Ming hold postdoctoral fellowships from Harvard and Dartmouth.
  • Approved medications: Centers utilize globally recognized drugs like Leqembi and Kisunla for early symptoms.
  • Facility standards: Leading hospitals maintain 300+ beds and over 60 specialized neurological departments.
  • Regulatory oversight: The National Health Commission mandates written informed consent and strict licensing protocols.

Bookimed Expert Insight: While many seek low-cost options, safety in China is tied to academic credentials rather than price. Our data shows that top-performing neurologists, such as Dr. Zheng Wei Hong, often hold dual roles as university professors and committee members for the Ministry of Health. Selecting a doctor with these institutional ties ensures the treatment follows national safety guidelines and uses verified pharmaceutical chains.

Patient Consensus: Patients emphasize the need for independent medical translators to bridge language gaps in public hospitals. They also recommend verifying clinical trial data before traveling for any experimental stem cell procedures.

What treatment modalities are currently offered for Alzheimer’s disease in China?

Alzheimer treatment in China includes anti-amyloid monoclonal antibodies like Lecanemab and unique domestic medications such as Sodium Oligomannate. Specialized centers provide stem cell therapy and neurostimulation. These modalities target amyloid plaques, gut microbiome regulation, and cognitive rehabilitation within modern tertiary-level facilities.

  • Pharmacological therapies: Approved drugs include Lecanemab, Donanemab, and the seaweed-derived oral medication Sodium Oligomannate.
  • Neuromodulation: Centers use non-invasive transcranial magnetic stimulation (rTMS) to improve memory and language.
  • Cellular therapy: Clinics in major cities like Tianjin offer stem cell therapy for neurorestoration.
  • Integrative medicine: Protocols combine Western neurology with acupuncture and herbal compounds like Huperzine A.

Bookimed Expert Insight: Leading neurologists like Dr. Shao Ming at Dr. Eber Brain Hospital often bring prestigious international training from Harvard and the University of Texas to Chinese treatment protocols. This background allows them to combine domestic drug innovations with Western diagnostic precision in complex neurology cases. Patients should look for doctors with such global credentials when seeking advanced neurophysiological monitoring.

Patient Consensus: Patients note that standard drugs are easily accessible in major cities, but emphasize that integrated TCM approaches like acupuncture often work best when combined with Western medicine. Families suggest focusing on Tier-1 city hospitals to ensure access to authentic medications and avoid counterfeit risks.

How is eligibility for Alzheimer’s therapy determined, and are there age or stage limitations?

Eligibility for Alzheimer’s therapy depends on a clinical diagnosis of mild cognitive impairment or early-stage dementia. Patients must prove amyloid-positive status via PET scans or cerebrospinal fluid analysis. While guidelines focus on adults aged 50 to 90, cognitive stage and overall health outweigh biological age.

  • Clinical stage: Eligibility requires early symptomatic stages including mild cognitive impairment or mild dementia.
  • Biological markers: Positive amyloid-beta plaques must be confirmed through brain imaging or fluid analysis.
  • Functional status: Candidates must maintain independence in basic daily activities like dressing or bathing.
  • Safety exclusions: Severe vascular disease or concurrent use of blood thinners often prevents eligibility.
  • Age range: Most therapies target ages 50 to 90 with case-by-case reviews for others.

Bookimed Expert Insight: Focus on tertiary centers in tier-1 cities like Beijing or Tianjin for complex diagnostics. Dr. Eber Brain Hospital in Tianjin features 63 departments specializing in neurological restoration. Specialized neurologists like Dr. Shao Ming at this facility have extensive international research experience in memory impairment. This high level of specialization is critical because general hospitals may delay the biomarkers testing required for early treatment.

Patient Consensus: Patients emphasize that the diagnosis process often takes over a year. Many regret waiting and advise seeking a neurologist immediately rather than relying on primary care visits. They note that being proactive with amyloid testing is the only way to catch the narrow window for newer therapies.

What side-effects or risks should patients anticipate with Alzheimer’s medications in China?

Patients should anticipate gastrointestinal distress or neurological changes from Alzheimer’s medications in China. Newer amyloid-targeting antibodies like lecanemab carry a 9.4% risk of microhemorrhages. Symptom-relieving drugs often cause nausea or insomnia. Specialized monitoring helps manage these risks safely within Chinese clinical settings.

  • Amyloid-related abnormalities: Lecanemab carries risks of brain swelling (3.1%) or microhemorrhages (9.4%).
  • Gastrointestinal distress: Donepezil and Galantamine frequently cause nausea, vomiting, and persistent diarrhea.
  • Neurological risks: Patients may experience vivid dreams, night terrors, agitation, or sudden dizziness.
  • Cardiac concerns: Drugs like rivastigmine may cause bradycardia or slow heart rate.

Bookimed Expert Insight: Coordination of care is vital when combining Western drugs with Traditional Chinese Medicine (TCM). Our data shows that top neurologists like Dr. Zheng Wei Hong at Xiamen Humanity Hospital specialize in both cognitive impairment and neuroimmunology. This dual expertise is crucial because internal research suggests herbal combinations can sometimes lead to unpredictable bleeding risks or increased sedation when used alongside standard prescriptions. We recommend patients verify all medications through hospital pharmacies to ensure authenticity and safety.

Patient Consensus: Many families report being surprised by heart rate drops or fainting. They emphasize the need to start with low doses and verify all medications at hospital pharmacies to avoid quality issues.

How long will I need to stay in China for evaluation and initial Alzheimer’s therapy?

International patients typically stay in China for 1 to 4 weeks for initial Alzheimer’s evaluation and therapy. This period covers specialized biomarker testing and neuroimaging. It also includes the start of protocols like stem cell therapy or specific localized drug monitoring. Professional medical support is essential for communication.

  • Diagnostic phase: Initial scans and cognitive testing usually take 3 to 7 days.
  • Treatment duration: Initial therapy cycles or infusions often require 1 to 2 additional weeks.
  • Safety monitoring: Facilities like Dr. Eber Brain Hospital provide inpatient observation to manage responses.
  • Visa requirements: Stays over 30 days for extended observation require an S2 medical visa.

Bookimed Expert Insight: While small clinics may offer 10-day diagnostic windows, quaternary centers like Dr. Eber Brain Hospital operate with over 400 doctors across 63 departments. This massive scale often means internal coordination takes longer but provides more thorough results. A 4-week stay is actually safer for patients traveling long distances to manage any initial treatment side effects.

Patient Consensus: Patients emphasize budgeting 6 weeks to avoid rushed protocols and account for potential language barriers. Many suggest securing travel insurance that covers experimental treatments to handle unexpected extensions or observation needs.

Will I be able to continue Alzheimer’s medication prescribed in China once I return home?

Continuing Alzheimer medication from China depends on local drug approval and customs rules. Globally approved drugs like Lecanemab are often transferable. However, China-specific treatments like Oligomannate or stem cell therapy protocols require a local neurologist assessment for long-term care in your home country.

  • Import limits: Most countries allow a 90-day supply for personal use at customs.
  • Mandatory documentation: Carry an English-translated prescription and a formal medical summary explaining diagnosis.
  • Local prescription: Home pharmacies cannot refill foreign prescriptions directly without local physician approval.
  • Generic availability: Identify medications by generic names to help local doctors find equivalent versions.

Bookimed Expert Insight: While China leads in neurorestorative research at facilities like Dr. Eber Brain Hospital, these advanced protocols often differ from Western standards. Our data shows that doctors like Dr. Zheng Wei Hong emphasize a transition period where home doctors perform fresh bloodwork before re-prescribing. Do not assume your home neurologist will continue a Chinese protocol without first reviewing these specific clinical records.

Patient Consensus: Patients note that keeping medications in original containers with English labels is vital for passing customs. Many recommend coordinating with a local neurologist before leaving China to avoid gaps in daily treatment.

Do I need special preparation or follow-up tests after returning home?

Clinical follow-up for Alzheimer's treatment in China typically involves virtual monitoring rather than mandatory in-person tests. Patients should prioritize rest and hydration before traveling home. Standard medical evaluations by a local neurologist are recommended within 1 to 3 months to track cognitive progress objectively.

  • Travel preparation: Focus on rest and hydration before long-haul flights after infusions.
  • Virtual monitoring: Establish communication via messaging apps for monthly symptom tracking with staff.
  • Cognitive assessments: Schedule independent exams like MoCA or MMSE with a local specialist.
  • Medication review: Discuss any clinic-recommended supplements with your primary physician upon return.

Bookimed Expert Insight: Chinese neurology centers like Dr. Eber Brain Hospital emphasize multidisciplinary approaches including rehabilitation. Because international data coordination is limited, patients should record their own baseline metrics before treatment. This creates a clear benchmark for local doctors to measure post-treatment improvements in motor function or memory.

Patient Consensus: Patients note that formal follow-up is often just a brief video call or phone quiz. Many recommend using independent cognitive apps and private scans at home to verify any neural changes described by the clinic.

Obtenez une consultation gratuite

Sélectionnez la meilleure façon de vous contacter